These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24297600)

  • 1. Release characteristics of quetiapine fumarate extended release tablets under biorelevant stress test conditions.
    Garbacz G; Kandzi A; Koziolek M; Mazgalski J; Weitschies W
    AAPS PharmSciTech; 2014 Feb; 15(1):230-6. PubMed ID: 24297600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance - case study of multimodal characterization of quetiapine fumarate tablets.
    Kulinowski P; Woyna-Orlewicz K; Rappen GM; Haznar-Garbacz D; Węglarz WP; Dorożyński PP
    Int J Pharm; 2015 Apr; 484(1-2):235-45. PubMed ID: 25701626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of pH, buffer capacity and ionic strength on quetiapine fumarate release from matrix tablets prepared using two different polymeric blends.
    Hamed R; AlJanabi R; Sunoqrot S; Abbas A
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1330-1342. PubMed ID: 28402145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach in distinguishing between role of hydrodynamics and mechanical stresses similar to contraction forces of GI tract on drug release from modified release dosage forms.
    Takieddin M; Fassihi R
    AAPS PharmSciTech; 2015 Apr; 16(2):278-83. PubMed ID: 25273030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms.
    Lu Z; Fassihi R
    AAPS PharmSciTech; 2017 Feb; 18(2):462-472. PubMed ID: 27106916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F; Holm P; Larsen F; Steffansen B
    Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
    Garbacz G; Rappen GM; Koziolek M; Weitschies W
    J Pharm Pharmacol; 2015 Feb; 67(2):199-208. PubMed ID: 25557626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biorelevant In Vitro Release Testing and In Vivo Study of Extended-Release Niacin Hydrophilic Matrix Tablets.
    Milanowski B; Hejduk A; Bawiec MA; Jakubowska E; Urbańska A; Wiśniewska A; Garbacz G; Lulek J
    AAPS PharmSciTech; 2020 Jan; 21(3):83. PubMed ID: 31989330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status.
    Guiastrennec B; Söderlind E; Richardson S; Peric A; Bergstrand M
    Pharm Res; 2017 Apr; 34(4):847-859. PubMed ID: 28155077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal approach to characterization of hydrophilic matrices manufactured by wet and dry granulation or direct compression methods.
    Kulinowski P; Woyna-Orlewicz K; Obrał J; Rappen GM; Haznar-Garbacz D; Węglarz WP; Jachowicz R; Wyszogrodzka G; Klaja J; Dorożyński PP
    Int J Pharm; 2016 Feb; 499(1-2):263-270. PubMed ID: 26752087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
    Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of dissolution behavior of diclofenac sodium extended release formulations under standard and biorelevant test conditions.
    Garbacz G; Weitschies W
    Drug Dev Ind Pharm; 2010 May; 36(5):518-30. PubMed ID: 19877827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irregular absorption profiles observed from diclofenac extended release tablets can be predicted using a dissolution test apparatus that mimics in vivo physical stresses.
    Garbacz G; Wedemeyer RS; Nagel S; Giessmann T; Mönnikes H; Wilson CG; Siegmund W; Weitschies W
    Eur J Pharm Biopharm; 2008 Oct; 70(2):421-8. PubMed ID: 18582568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets.
    Walsh PL; Bothe JR; Bhardwaj S; Hu M; Nofsinger R; Xia B; Persak S; Pennington J; Bak A
    Drug Dev Ind Pharm; 2016; 42(5):836-44. PubMed ID: 26339722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the dissolution of metaxalone tablets (Skelaxin) using USP Apparatus 2 and 3.
    Cacace J; Reilly EE; Amann A
    AAPS PharmSciTech; 2004 Feb; 5(1):E6. PubMed ID: 15198527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the Dissolution Profile of Gliclazide Modified-Release Tablets Using Different Apparatuses and Dissolution Conditions.
    Skripnik KKS; Riekes MK; Pezzini BR; Cardoso SG; Stulzer HK
    AAPS PharmSciTech; 2017 Jul; 18(5):1785-1794. PubMed ID: 27800567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIVC for Extended Release Hydrophilic Matrix Tablets in Consideration of Biorelevant Mechanical Stress.
    Mohylyuk V; Goldoozian S; Andrews GP; Dashevskiy A
    Pharm Res; 2020 Oct; 37(11):227. PubMed ID: 33094368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.